Fueled at least in part by exceptionally strong IPO and M&A markets, hedge funds, venture capitalists, private equity firms and corporate investors are committing more time and money into privately held medical devices companies, according to a new “Healthcare Investments and Exits” report issued by Silicon Valley Bank. The report examining the first half of […]
Silicon Valley Bank
Medtronic’s Kowal explains how remote medtech got its groove back
In this week’s DeviceTalks Weekly Podcast, Dr. Robert Kowal CMO of Medtronic’s cardiac rhythm and heart failure business and vice president of medical affairs, explains how new tech, savvy patients, eager physicians and, yes, COVID-19, has fueled a renaissance for remote technology, once seen as a mature, staid business. Kowal, who left clinical practice to […]
How is COVID-19 affecting medtech deals?
Fewer medical device companies are securing their first big venture capital investments — or engaging in large mergers — amid the COVID-19 pandemic, according to recently released reports from Silicon Valley Bank and PwC. The medical device industry saw 38 Series A investments worth $279 million during the first half of 2020, down from 45 […]
Medtech startups rack up strong VC totals in Q1, but future uncertain, SVB says
Medtech startups raising venture capital in the first quarter kept the strong pace from 2019, according to an analysis by Silicon Valley Bank. But the uncertainty over the pandemic likely will slow down fund-raising in the second quarter. In an interview with DeviceTalks Weekly Podcast, Jonathan Norris, managing director, SVB Life Sciences, says SVB recorded […]
DeviceTalks Weekly: Ep. 8 – AdvaMed‘s Scott Whitaker on pandemic readiness, Jon Norris of SVB shares Q1 VC data
In this week’s episode of DeviceTalks Weekly, Scott Whitaker, CEO and president of AdvaMed, shares concerns he had over how the federal government would work with the medtech industry during the pandemic crisis. Does he feel the medtech industry was treated fairly? How does he see the federal government and medtech industry working together in […]
It’s another big year for medtech M&A
The breakneck pace of consolidation continued in 2017, significantly reducing the pool of Big 100 companies, as cash-laden companies scooped up smaller firms. The medical device industry may not be keeping pace with initial public offerings in biotech, but medtech is holding its own when comes to mergers and acquisitions, according to industry watchers. Boston […]
Venture investing in medtech and digital health: Here’s advice from the trenches
Medtech entrepreneurs agree that it’s still tough to find funding at the Series A level. Here’s their advice about how to find it. Bill Evans Competition for medtech venture investing is fierce, at the same time that traditional investors pull back from the space. To get to the bottom of what’s going on, I reached […]
Medtech venture investing trends: Here’s what you need to know
Ask any early-stage medtech or digital health entrepreneur, and they’ll tell you how tough it is. There’s tremendous competition for venture investing, coupled with a pullback by previously traditional investors in this space. Bill Evans While venture investment in medtech and digital health has recovered since the financial crisis of a decade ago — setting […]
Report: Big data, AI hold “greatest promise” for healthcare tech
Big data and artificial intelligence will have the greatest impact in the health-tech industry in the year ahead, according to a survey released yesterday. The survey, performed by Silicon Valley Bank, polled 122 founders, execs and investors in health care technology companies about the biggest challenges, most promising technology and biggest growth sectors in the […]
Silicon Valley Bank’s Ben Johnson talks early-stage medtech investment slump | Medtech funding for the week of September 22, 2014
What’s behind the slump in early-stage medtech investment?
It’s a hard world out there for those looking to turn their cutting edge medical device ideas into commercial products, with investors shying away from early-stage companies in favor of more established medtech enterprises.
